Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Netscientific Plc LSE:NSCI London Ordinary Share GB00BN4R5Q82 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.50 -5.1% 46.50 38,572 14:00:05
Bid Price Offer Price High Price Low Price Open Price
45.00 48.00 49.00 46.50 49.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.74 -3.63 -5.70 7
Last Trade Time Trade Type Trade Size Trade Price Currency
14:00:37 O 1,731 47.80 GBX

Netscientific (NSCI) Latest News

More Netscientific News
Netscientific Investors    Netscientific Takeover Rumours

Netscientific (NSCI) Discussions and Chat

Netscientific Forums and Chat

Date Time Title Posts
28/2/202116:51NetScientific PLC2,807
24/1/202119:11NETSCIENTIFIC10
15/6/201910:31Netscientific16

Add a New Thread

Netscientific (NSCI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-03-05 14:00:3847.801,731827.42O
2021-03-05 12:58:1147.803,6531,746.13O
2021-03-05 12:36:5947.801,000478.00O
2021-03-05 11:27:2646.00820377.20O
2021-03-05 10:53:3346.4910,7374,991.63O
View all Netscientific trades in real-time

Netscientific (NSCI) Top Chat Posts

DateSubject
06/3/2021
08:20
Netscientific Daily Update: Netscientific Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker NSCI. The last closing price for Netscientific was 49p.
Netscientific Plc has a 4 week average price of 46.50p and a 12 week average price of 42.40p.
The 1 year high share price is 73.50p while the 1 year low share price is currently 0.75p.
There are currently 15,017,188 shares in issue and the average daily traded volume is 23,533 shares. The market capitalisation of Netscientific Plc is £6,982,992.42.
23/2/2021
19:28
the stigologist: NSCI One of few stocks up today In a 'bio/med tech 'bull market' it's around the same price as during Covid crash around March last year But it has some decent investments Glycotest - Liver cancer diagnostic with Fosun owning c.40% and advancing it in China PDS Biotech - Cancer immunotherapy + Covid/Flu vaccine play ProAxsis - no idea but it's received about £1m in Government funding so must have something commercialisable ?! NSCI top 2 investors own 60% of the stock Glycotest I believe could be the jewel in the crown with Market Opportunity of $1bn+ p.a. NSCI at £9m Mkt Cap seems too cheap as a 60% play on Glycotest alone Golden Cross incoming...
18/2/2021
22:58
the stigologist: I don't really rate ProAxsis but there is a case for saying any one of NSCIs 3 main investments could be game changing to net asset valuation which already stands at huge premium to current share price
10/2/2021
10:22
the stigologist: All the jonny-come-latelies who weren't here last week in the 40s now making out they are experts lolz PDSB is only the No.2 investment here (albeit potential game changing tech with $1bn+ potential) Glycotest is the one that could really blow the doors off for NSCI as NSCI own 50% of Glycotest vs just 5% of PDSB Come on Dr Iliev pull your finger out SPAC Glycotest onto NASDAQ !
09/2/2021
21:31
loafofbread: With today's close, PDSB is pretty much our market cap and we have another £14M of assets. Insane volume so our 1,282,000 shares nice and liquid. NSCI Share price 52p, NAV £1.50. A repost of my Feb 1st note. If you have a look at the results and placing docs you come up with a slightly better NAV than the current share price A lot will depend on PDSB, but as we stand this evening. A couple of things to remember. Only 15M shares in issue Recent placing at 65p to buy EMV Capital. Concert party hold more than 50% of the shares so limited free float if it starts to move. EMV Capital portfolio £3.4M Cash £1.5M 3 main holdings £1.1M (Cyto,Edibone,G-Tech) Glycotest £5.0M (more now as we hold a higher %) PDSB £3.25M @ $3.00 a share. £14.25M I can't find a value for Proaxis, 100% owned, but as it just won a £300K grant and has new sales deals for USA and a few other areas, lets say £3M. Add in todays PDSB rise, which is another £650K and you get close to £18M. M Cap today less than £7M. PDSB has some near term news flow due over the next few months which could send it parabolic. Discuss!
04/2/2021
20:49
the stigologist: Yep lot of people didn't understand the Trial result or that it is actually one of the least important of PDSBs 3 ongoing clinical trials NSCI in the past described PDSB as a game changing US technology Company and the potential of their tech in cancer and infectious disease (e.g. covid) vaccines is huge PDSB Mkt Cap c.$60m Valuation of any Company with any half decent covid vaccine $1bn+ If PDSB becomes a $1bn Company NSCI's PDSB stake will be worth c.$60m vs a current NSCI Mkt Cap of £7m PDSB isn't even the biggest NSCI investment that being Glycotest which could be a $1bn+ Company and is actually c.50% held by NSCI Imagine if Glycotest IPO-ed on NASDAQ right now ! NSCI stake worth $500m? vs current Mkt Cap £7m There is a reason 2 guys own 50% of the stock here Not something £500 traders like Dave would appreciate
01/2/2021
23:59
loafofbread: If you have a look at the results and placing docs you come up with a slightly better NAV than the current share price A lot will depend on PDSB, but as we stand this evening. A couple of things to remember. Only 15M shares in issue Recent placing at 65p to buy EMV Capital. Concert party hold more than 50% of the shares so limited free float if it starts to move. EMV Capital portfolio £3.4M Cash £1.5M 3 main holdings £1.1M (Cyto,Edibone,G-Tech) Glycotest £5.0M (more now as we hold a higher %) PDSB £3.25M @ $3.00 a share. £14.25M I can't find a value for Proaxis, 100% owned, but as it just won a £300K grant and has new sales deals for USA and a few other areas, lets say £3M. Add in todays PDSB rise, which is another £650K and you get close to £18M. M Cap today less than £7M. PDSB has some near term news flow due over the next few months which could send it parabolic. Discuss!
16/11/2020
18:12
kingston78: Consolidation of shares is usually a prelude to a disaster to the share price. The reverse is also true to bonus (split) shares. A strong company will have a high share price to the extent that investors find it difficult to buy in any meaningful quantity (this is psychological) so the company splits the shares say, from 1 to 10 shares (same value), but as there is pent up demand the share price after the split continues to go up. Unfortunately NetScientific consolidated its shares to make it look more respectable, but to no avail.
06/8/2020
10:29
kingston78: It is common for AIM companies to raise fresh capital by way of a placing, which is quicker and cheaper than a rights issue. The placing price is always lower than the prevailing share price to attract investors. This does not necessarily mean that the share price will drift lower. I have seen instances where a well funded company after a placing goes on to succeed because it has the funds to invest. I hope this is the case with NSCI.
20/7/2020
20:37
baz9707: 100m mkt cap PDSB 7m to NSCI share price will be in double figures.
16/4/2020
19:27
the stigologist: I don't think it is any surprise that We've had new Management (entrepreneurial Chatham House fellow Dr Iliev) Dr Iliev joins PDS Biotech Board PDS Announced change of strategy to target COVID19 I think the reason the NSCI share price looks like it might 'overshoot' fundamental value is that the market (and insiders) may think NSCI is now set to ADD VALUE to its holdings rather than be a passive investor. Glycotest seems to me to be the seriously big driver. Earlier NSCI Investor presentations suggested valuation potential for Glycotest of c.$400m IF (big IF) NSCI achieve that then their holding in Glycotest will be worth c.$200m Versus current NSCI Mkt Cap of £12m Many people have suggested ProAxsis might be a Covid play. It might be a secondary one. Could create some excitement. On that I'm yet to be convinced.
Netscientific share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
NSCI
Netscienti..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210306 09:44:43